# Enveric Biosciences, Inc.: overview ENVB · Nasdaq · CIK 890821 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/envb.md) · [Financials](/companies/envb/financials.md) · [Filings](/companies/envb/filings.md) · [Insiders](/companies/envb/insiders.md) Latest reported revenue: [$8.5m](/filings/0001493152-20-021409.md) for Q3 FY2020, three months to 2020-09-30, from the 10-Q filed Nov 16, 2020 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-20-021409). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(43.10)](/filings/0001493152-25-023540.md) | not reported | [(14.58)](/filings/0001493152-26-023353.md) | [(11.65)](/filings/0001493152-26-038418.md) | [(10.81)](/filings/0001493152-25-023540.md) | not reported | [(1.08)](/filings/0001493152-26-023353.md) | [(0.76)](/filings/0001493152-26-038418.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.07)](/filings/0001493152-22-008510.md) | [(13.00)](/filings/0001493152-24-011210.md) | [(121.29)](/filings/0001641172-25-001296.md) | [(228.48)](/filings/0001493152-26-013294.md) | [(36.24)](/filings/0001493152-26-013294.md) | | Free cash flow | $m | [(11.6)](/filings/0001493152-23-020625.md) | [(17.7)](/filings/0001493152-24-011210.md) | [(14.1)](/filings/0001641172-25-001296.md) | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/envb/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Sio Capital Management, LLC](/funds/1482416.md) | 2026-06-30 | $248.4k | 180,000 | | New +180,000 | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $138.0k | 100,002 | | New +100,002 | | [AdvisorShares Investments LLC](/funds/1425930.md) | 2026-06-30 | $48.9k | 35,417 | | Added +18,443 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $44.2k | 32,058 | | New +32,058 | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $44.2k | 32,000 | | New +32,000 | | [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $41.6k | 30,142 | | New +30,142 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $26.2k | 18,990 | | New +18,990 | | [StoneX Group Inc.](/funds/913760.md) | 2026-06-30 | $21.9k | 11,814 | | New +11,814 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $20.6k | 14,912 | | New +14,912 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $19.3k | 13,965 | | New +13,965 | ## Recent filings [All 891 filings](/companies/envb/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-14 | 16:21 ET | [10-Q](/filings/0001493152-26-038418.md) | Quarterly report, period 2026-06-30 | 0001493152-26-038418 | | 2026-08-14 | 16:15 ET | [8-K](/filings/0001493152-26-038385.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-038385 | | 2026-06-09 | 17:16 ET | [8-K](/filings/0001493152-26-027976.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-027976 | | 2026-06-09 | 17:53 ET | [8-K](/filings/0001493152-26-027781.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-027781 | | 2026-05-29 | 16:13 ET | [8-K](/filings/0001493152-26-026364.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-026364 | | 2026-05-15 | 08:05 ET | [10-Q](/filings/0001493152-26-023353.md) | Quarterly report, period 2026-03-31 | 0001493152-26-023353 | | 2026-05-15 | 08:00 ET | [8-K](/filings/0001493152-26-023345.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-023345 | | 2026-04-30 | 16:02 ET | [8-K](/filings/0001493152-26-020410.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-020410 | | 2026-04-20 | 18:15 ET | [8-K](/filings/0001493152-26-017960.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-017960 | | 2026-04-14 | 16:05 ET | [DEF 14A](/filings/0001493152-26-016543.md) | Proxy statement, period 2026-04-14 | 0001493152-26-016543 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-013294.md), filed Mar 27, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 890821 - Tickers: ENVB - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.